Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class (Prostacyclin & Prostacyclin Analogs, SGC Stimulators, ERA, PDE-5), By Region, And Segment Forecasts, 2019 - 2026

Industry Insights

The global pulmonary arterial hypertension market size was valued at USD 6.0 billion in 2018 and is expected to register a CAGR of 5.6% over the forecast period. Changing consumer lifestyle, along with increasing geriatric population, is expected to drive the growth.

Supportive government initiatives for the development of orphan drugs (drugs for rare diseases) are projected to support the market growth. For instance, the Rare Disease Act 2002 and Orphan Drug Act (ODA) 1983 in U.S. offer incentives, such as tax credits, for the development of orphan drugs. The Orphan Drug Act enables tax credits up to 50% of total R&D cost, funding for R&D, protocol assistance, and waiver in Food and Drug Administration (FDA) fees and clinical tax incentives. These incentives foster pharmaceutical companies to invest in development of orphan drugs.

The patient-focused Drug Development (PFDD) initiative highlights the power and advocacy for patient care in U.S. Under these initiatives, meetings were held with a group of people suffering from rare diseases. The agenda of these meetings was to understand disease severity, its impact on patients’ lives, and available treatment options. This initiative is also undertaken to create awareness about rare diseases in U.S., which helped people undergo diagnosis and avail treatment of rare diseases, including Pulmonary Arterial Hypertension (PAH).

Changing lifestyle of consumers in terms of lack of physical activity and increased consumption of alcohol, tobacco, and fast food products increases the chances of developing hypertension and high blood pressure. The increased blood pressure in turn, gives rise to various diseases such as stroke and heart attacks. Hypertension is perceived as a variable health risk and is often related with morbidity and mortality due to its alliance with cardiovascular diseases.

Drug Class Insights

Pulmonary arterial hypertension includes various drugs such as soluble guanylate cyclase (SGC) stimulators, prostacyclin and prostacyclin analogs, phosphodiesterase 5 (PDE-5), and endothelin receptor antagonists (ERA). ERA dominated the market in 2018 with a 44.8 share of the overall revenue. Opsumit and Tracleer target ETB and ETA receptors, whereas Volibris/Letairis targets the ETA receptor.

The segment of prostacyclin and its analogues is expected to dominate the pulmonary arterial hypertension market over the forecast period owing to the sharp increase in the sales of these drugs due to the development projected in oral prostacyclin agents, such as Orenitram and Uptravi.

Regional Insights

North America dominated the market in 2018 due to the developed healthcare infrastructure in U.S. that facilitated access to advanced therapeutics. Moreover, increased awareness, high diagnosis rate, and supportive government initiatives governed the growth in this region.Well planned reimbursement structure and high awareness resulted in excellent diagnosis rate. Besides, supportive legislations like Rare Disease Act 2002 and the Orphan Drug Act (ODA) 1983 in U.S. fostered the development of novel medication for PAH.

Asia Pacific is anticipated to expand at the fastest CAGR of 6.7% over the forecast period. This can be attributed to improving healthcare systems, rapid economic developments, and huge population base. Furthermore, high disease burden such as HIV and diabetes that are responsible for the development of the PAH supports the market growth in this region.

Pulmonary Arterial Hypertension Market Share Insights

Some of the players in the market are Actelion Pharmaceuticals, Ltd.; Novartis International AG; Gilead Sciences, Inc.; United Therapeutics Corporation; GlaxoSmithKline Plc. (GSK); Pfizer, Inc.; Dong-A ST Co., Ltd.; Merck Sharp & Dohme Corp; Bayer HealthCare; and Arena Pharmaceuticals. Key strategies undertaken by the market players to stay competitive include new product development, collaboration, and geographical expansion. For instance, in October 2014, Merck Sharp & Dohme Corp. sold its consumer care business to Bayer AG. This initiative was undertaken to market and develop portfolio of SGC modulators.

Report Scope

Segments Covered in the Report:

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026.For the purpose of this study, Grand View Research, Inc. has segmented the global pulmonary arterial hypertension market report on the basis of drug class and region:

• Drug Class Outlook (Revenue, USD Million, 2015 - 2026)

  • Prostacyclin & Prostacyclin Analogs

  • SGC Stimulators

  • ERA

  • PDE-5

• Regional Outlook (Revenue, USD Million, 2015 - 2026)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • Italy

    • Spain

    • France

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE